All Episodes
Drug Discovery AI Talk — 67 episodes
#67. Does Size Matter?
#66. Quantitative Systems Pharmacology
#65. Orbiting around Big Pharma
#64. Foundation Models
#63. The Era of NAMs
#62. Predicting Toxicity
#61. AI Era Evidence Flywheel
#60. Cracking the "Undruggable" Target
#59. Drug Discovery AI Teammates
#58. Do We Need Mavericks?
#57. Do You Turst your AI?
#56. Ethics in AI for Drug Discovery
#55. AI for Drug Patents
#54. Companion Diagnostic Biomarkers
#53. The Math of AI Drug Discovery
#52. Benchmarking AI for Drug Discovery
#51. OpenClaw for BioPharma
#50. Atomic Level Drug Design
#49. From Prompts to Drugs
#48. Virtual Clinical Trials
#47. The Silicon Alchemist
#46. Top Ten AI Research Papers in 2025
#45. Genome-wide Virtual Screening
#44. Modern Drug Delivery Platforms
#43. Antibody-Drug Conjugate
#42. Biologic Immunogenecity
#41. CAR T Cell Therapy
#40. AI-Guided Alzheimer's Trial Design Lessons
#39. AI Drug Discovery Career Roadmap: Anti-Fragile Skills
#38. US and China Rivalry
#37. Open Source Drug Discovery 2.0
#36. Future of IND Filings
#35. AI-Driven Drug Repurposing
#34. AI Agents Transform Drug Discovery
#33. Modern Therapeutic Modalities
#32. AI Drug Discovery Startups
#31. Neuroendocrine Peptide Analogs
#30. Autism Data Science Initiative: Unlocking Precision Treatment
#29. Cystic Fibrosis: A Blueprint for Rare Disease Cures
#28. Eroom's Law
#27. Druggability and AI
#26. AI for Combination Drug Therapy
#25. Overall Survival Focus and AI Oncology Drugs
#24. Digital Twins: Transforming Clinical Trials
#23. AI and the Decentralization of Drug Discovery
#22. Molecular Glue Degraders
#21. N-of-1: the Future of Personalized Drug Development
#20. Ensifentrine's Triumph: An AI Blueprint for Drug Development
#19. AI Agents: Transforming Drug Discovery through Collaborative Partnerships
#18. First-in-Class vs. Best-in-Class AI Drug Discovery Strategies
#17. Atul Butte: Pioneer of Data-Driven Medicine
#16. Can AI scientists revolutionize drug discovery?
#15. AAV 2.0: Next-Generation Gene Therapy Vectors
#14. Global Trial & Error: Can AI Help? (05/30/2025)
#13. Chemical Space Docking: Is Bigger Better? (05/23/2025)
#12. Can AI help develop the next-generation diabetes drug? (05/16/2025)
#11. TYK2 Inhibitor Landscape and Pipeline (05/09/2025)
#10. Biomedical Research Funding and Innovation: May 2025 Senate Appropriation Committee Hearing (05/06/2025)
#9. Patent Dispute and Protections in the New AI Era (05/02/2025)
#8. Immune Response, Vaccines, and Autism: An Unbiased Scientific Review (04/25/2025)
#7. FDA Roadmap: Reducing Animal Testing in Preclinical Studies (04/22/2025)
#3. FDA Guidance: AI in Drug and Biological Product Regulatory Decisions (01/30/2025)
#2. 2024 Fierce 50: Innovations and Breakthroughs in Biopharma (01/01/2025)
#5. GLP-1 Medications: Current Status and Future Metabolic Therapies (03/15/2025)
#1. AI Drug Discovery in 2025: Trump, Kennedy, and Health Policy Outlook (11/14/2024)
#4. Alzheimer's Drug Development: Mechanisms, IP, and the Evolving Landscape (02/10/2025)
#6. AI in Drug Discovery - Reality Check (04/21/2025)